SONN

Sonnet BioTherapeutics Holdings, Inc.

0.94 USD
-0.04 (-4.08%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sonnet BioTherapeutics Holdings, Inc. stock is down -37.33% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 18 June’s closed higher than May. 100% of analysts rate it a buy.

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. develops platform for biologic medicines of single or bispecific action. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.